Home » Stocks » ALEC

Alector, Inc. (ALEC)

Stock Price: $25.56 USD 0.22 (0.87%)
Updated Aug 3, 2021 1:14 PM EDT - Market open
Market Cap 1.92B
Revenue (ttm) 18.04M
Net Income (ttm) -202.38M
Shares Out 79.39M
EPS (ttm) -2.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $25.56
Previous Close $25.34
Change ($) 0.22
Change (%) 0.87%
Day's Open 25.31
Day's Range 24.45 - 26.24
Day's Volume 454,702
52-Week Range 9.12 - 43.32

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Alector Inc (NASDAQ: ALEC) detailed early data from its lead drug, AL001, INFRONT-2 Phase trial at the Alzheimer's Association International Conference (AAIC 2021) Patients with one type of frontotempor...

4 days ago - Benzinga

AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients

5 days ago - GlobeNewsWire

Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET

1 week ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Alector, Inc. (ALEC).

3 weeks ago - Zacks Investment Research

The company has yet another fine July trading day thanks to a Citigroup analyst.

3 weeks ago - The Motley Fool

Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.

Other stocks mentioned: GSK
4 weeks ago - Zacks Investment Research

Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ??? for treating various neurodegenerative diseases.

Other stocks mentioned: GSK
4 weeks ago - Zacks Investment Research

Alector (ALEC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 weeks ago - Zacks Investment Research

It's not every day that a small biotech announces a major collaboration deal with a deep-pocketed pharmaceutical giant.

Other stocks mentioned: GSK
1 month ago - The Motley Fool

One of these companies is making big waves.

Other stocks mentioned: GSK
1 month ago - The Motley Fool

Alector (ALEC) stock is rocketing higher on Friday after the biotechnology company announced a partnership with GlaxoSmithKline (GSK). The post ALEC Stock: 12 Things to Know About Alector as GSK News Se...

Other stocks mentioned: GSK
1 month ago - InvestorPlace

Alector Inc (NASDAQ: ALEC) and GlaxoSmithKline plc (NYSE: GSK) have announced a global collaboration for the development and commercialization of two monoclonal antibodies designed to elevate progranuli...

Other stocks mentioned: GSK
1 month ago - Benzinga

SOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYSE: GSK), today announced a strategic global collaboration for the d...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M....

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it will host a virtua...

2 months ago - GlobeNewsWire

Alector (ALEC) delivered earnings and revenue surprises of 2.94% and -35.93%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced business updates and finan...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M...

4 months ago - GlobeNewsWire

Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis ...

Other stocks mentioned: CLVS, MRKR
4 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participan...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that chief business offic...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today provided a preview of its planned c...

6 months ago - GlobeNewsWire

Alector is a leader in neuroimmunology drug development. This has enabled the company to build a pipeline of medicines pursuing large and important markets from dementia and Alzheimer's.

7 months ago - Seeking Alpha

Alector, Inc (Nasdaq: ALEC) is a clinical-stage biopharmaceutical company focused on immuno-neurology, immune dysfunction studies related to degenerative brain disorders. Alector has 4-clinical phase th...

Other stocks mentioned: ABBV
7 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., c...

8 months ago - GlobeNewsWire

Alector (ALEC) delivered earnings and revenue surprises of -24.07% and -22.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and fin...

8 months ago - GlobeNewsWire

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that an independent arbit...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of the Compa...

9 months ago - GlobeNewsWire

Alector (ALEC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of manage...

10 months ago - GlobeNewsWire

Baby boomers have a reputation of being old and therefore irrelevant. However, this powerful and influential generation can spark huge demand for many stocks to buy.

Other stocks mentioned: AIG, AMP, LVS, RCL, SCI, UAL, WELL ...
11 months ago - InvestorPlace

Alector (ALEC) delivered earnings and revenue surprises of -11.54% and -64.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and f...

11 months ago - GlobeNewsWire

Alector Looks Like A Buy After Huge Selloff

11 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D.,...

11 months ago - GlobeNewsWire

Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.

1 year ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced preliminary data from i...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced dosing of the first pat...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the company will h...

1 year ago - GlobeNewsWire

Alector (ALEC) delivered earnings and revenue surprises of -10.42% and -32.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical- stage biotechnology company pioneering immuno-neurology, today announced business highlights and...

1 year ago - GlobeNewsWire

Is (ALEC) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company and leader in the discovery and development of therapeutics that ha...

1 year ago - GlobeNewsWire

Alector (ALEC) delivered earnings and revenue surprises of -2.27% and -37.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) today announced the addition of Paula Hammond, Ph.D., to the Company’s Board of Directors. Dr. Hammond is t...

1 year ago - GlobeNewsWire

Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 7, 2019
CEO
Arnon Rosenthal
Employees
181
Stock Exchange
NASDAQ
Ticker Symbol
ALEC
Full Company Profile

Financial Performance

In 2020, Alector's revenue was $21.10 million, a decrease of -0.57% compared to the previous year's $21.22 million. Losses were -$190.23 million, 80.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Alector stock is "Strong Buy." The 12-month stock price forecast is 38.75, which is an increase of 51.60% from the latest price.

Price Target
$38.75
(51.60% upside)
Analyst Consensus: Strong Buy